ImmunityBio's Manufacturing Breakthrough Fuels Pipeline Expansion

ImmunityBio has achieved a significant milestone beyond its already approved drug, ANKTIVA. On March 13, 2026, the biotechnology firm announced the successful validation of a scalable manufacturing platform for its next-generation natural killer (NK) cell therapies. Following this news, the company's equity surged by more than 9 percent.

Commercial Momentum and Financial Standing

This technical advancement comes as ImmunityBio builds a stronger commercial foundation. For the full year 2025, ANKTIVA generated net product revenue of $113 million—a staggering increase of approximately 700 percent over the prior year, driven by a 750 percent growth in unit sales. The therapy is now approved in 33 countries across four jurisdictions and, in January 2026, received the first global conditional SFDA approval for metastatic non-small cell lung cancer.

Further bolstering its commercial prospects, ImmunityBio submitted a supplemental Biologics License Application (BLA) to the FDA on March 9, 2026, for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer. The FDA acknowledged the submission and requested additional efficacy and long-term data but did not mandate new clinical studies. The company reported cash and marketable securities of $242.8 million and holds patent protection extending to 2035 and beyond.

While the EBIT margin stands at -278.4 percent, indicating profitability is not an immediate focus, the 99.3 percent gross margin reflects the high product value of ANKTIVA. The newly validated M-ceNK platform now expands the development portfolio from a single approved product toward a broader cell therapy pipeline.

A Scalable Solution for Cell Therapy Production

Should investors sell immediately? Or is it worth buying ImmunityBio?

The core of the announcement centers on manufacturing capability. Historically, autologous cell therapies have been considered complex and difficult to scale. ImmunityBio's completed NK2022 and NK2023 programs have established a process that can yield up to five billion NK cells from a single leukapheresis collection. This output is sufficient for eight to ten therapeutic doses within approximately twelve days, directly addressing a key industry bottleneck.

These programs involved a total of 74 participants, including healthy donors and cancer patients. Ten cancer patients received their processed cells via the NK enrichment procedure, resulting in 23 administered doses. No serious adverse events were reported. Notably, NK cells derived from cancer patients demonstrated cytotoxic activity comparable to those from healthy donors when tested against NK-resistant cell lines from various tumor types, including breast, ovarian, and brain cancers.

Supporting Preclinical and Clinical Data

Concurrent with the production news, researchers from the National Cancer Institute presented new data at the AACR IO Annual Meeting 2026 on combining M-ceNK cells with ANKTIVA. In two xenograft models for small cell lung cancer (SCLC), the combination achieved statistically significant reductions in tumor volume. A tissue analysis further revealed that 62 percent of neuroendocrine tumors lack MHC class I expression. This makes them resistant to T-cell-based immunotherapies but susceptible to NK-cell-mediated killing, identifying a clearly defined patient population with an unmet therapeutic need.

In a related development, ImmunityBio concluded its Phase I study, QUILT-3.076, which investigated M-ceNK in combination with ANKTIVA in patients with relapsed or refractory tumors and confirmed post-infusion safety.

Ad

ImmunityBio Stock: New Analysis - 17 March

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated ImmunityBio analysis...